Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved.

1. PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can
involve the nail unit (nail matrix, nail bed, or nail plate). DO isn’t considered life-threatening, however
can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO
patients can be identified as having thick or brittle nails along with discoloration (white and opaque).
Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment
are achieved.
Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the
incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par
safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to
withstand existing generic options. These therapies are also expected to drive an increase in total drug
treatment rates in the US market.
Scope
Overview of DO, including epidemiology, etiology, general symptoms from infection, and disease
management recommendations and guidelines. Annualized DO market revenue, annual cost of therapy and
treatment usage pattern data from 2012 and forecast for ten years to 2022. Key topics covered include strategic
competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the
DO market. Pipeline analysis: comprehensive data split across different phases, and emerging trends,
specifically new therapies with novel routes of administration. Analysis of the current and future market
competition in the US DO market. Insightful review of the key industry and governmental drivers, restraints
and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and
high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,
patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10
year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our
models support data presented in the reports and the complete methodology is outlined in the report and the
model.
*Model only available with site and global license purchases.
Key Findings
Generic therapies are expected to pose as a considerable threat to upcoming topical therapies because of
their shorter treatment duration. The first wave of new pipeline candidates will increase drug treatment rates as
physicians begin to opt for more safer options for treatment. Individual compliance, patient co-morbidities,
and insurance payers function as important considerations in assessing the treatment algorithm for every
patient.
Key Questions Answered in this Report
How big of an impact will topical agents have on the DO market? What do key opinion leaders think of this
paradigm shift? What new product is expected to become the market leader during the forecast period? How
will this impact the existing generic therapies? How will a change in the route of administration change the
PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

2. uptake of drugs in the US market? What are the primary unmet needs that exist in the market according to key
opinion leaders? What alliance opportunities exist in this market for a company looking to tap into the DO
market?
Key Benefits
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by
understanding the trends shaping and driving the US DO market. Drive revenues by understanding the key
trends, innovative products and technologies, market segments, and companies likely to impact the US DO
market in future. Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors. Identify emerging players with
potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the US DO market from 2012-2022. Organize your sales and marketing efforts by
identifying the market categories and segments that present maximum opportunities for consolidations,
investments and strategic partnerships.
table Of Contents
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology And Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality Of Life
3.2 Symptoms
4 Epidemiology
4.1 Risk Factors And Comorbidities
4.1.1 Poor Peripheral Circulation Is Greater In Older Men
4.1.2 Household Contact With Other Do Patients Increases Risk Of Infection 2.5 Times
4.1.3 Immunosuppression Increases Susceptibility To Do Infections
PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

3. 4.1.4 Prevalence Of Dermatophytic Onychomycosis Is Higher In Diabetics Than In
non-diabetics
4.2 Global Trends
4.3 Forecast Methodology
4.3.1 Sources Used
4.3.2 Forecast Assumptions And Methods
4.3.3 Sources Not Used
4.4 Epidemiology Forecast (2012–2022)
4.4.1 Prevalent Cases Of Dermatophytic Onychomycosis
4.4.2 Age-specific Prevalent Cases Of Dermatophytic Onychomycosis
4.4.3 Sex-specific Prevalent Cases Of Dermatophytic Onychomycosis
4.5 Discussion
4.5.1 Epidemiological Trends
4.5.2 Limitations Of The Analysis
4.5.3 Strengths Of The Analysis
5 Disease Management
5.1 Treatment Overview
5.1.1 Diagnosis
5.1.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles
6.3.1 Terbinafine
6.3.2 Itraconazole
6.3.3 Fluconazole
6.3.4 Ketoconazole
6.3.5 Griseofulvin
6.3.6 Ciclopirox
7 Opportunity And Unmet Need
7.1 Overview
7.2 Unmet Needs
7.2.1 Unmet Need: Efficacious Oral And Topical Treatments
7.2.2 Unmet Need: Clinical Safety
7.2.3 Unmet Need: Patient Awareness
7.2.4 Unmet Need: Shorter Treatment Duration
7.2.5 Unmet Need: Higher Treatment Rates
PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

4. 7.2.6 Unmet Need: Prescribing Guidelines
7.2.7 Unmet Need: Differential Diagnosis
7.3 Unmet Needs Gap Analysis
7.4 Opportunities
7.4.1 Opportunity: Decreased Frequency Of Dosing
7.4.2 Opportunity: Combinatorial Approaches To Treatment
8 Clinical Pipeline Assessment
8.1 Overview
8.2 Clinical Trials By Phase And Trial Status
8.3 Promising Drugs In Clinical Development
8.3.1 Efinaconazole
8.3.2 Tavaborole
8.3.3 Tdt-067
8.3.4 Luliconazole
8.3.5 Albaconazole
9 Current And Future Players
9.1 Overview
9.2 Trends In Corporate Strategy
9.3 Company Profiles
9.3.1 Valeant Pharmaceuticals International
9.3.2 Topica Pharmaceuticals
9.3.3 Anacor Pharmaceuticals
9.4 Late-stage Competition
9.4.1 Celtic Pharmaceutical Holdings
9.4.2 Palau Pharma
9.5 Early-stage Competition
9.5.1 Merck
9.5.2 Apricus Biosciences
10 Market Outlook
10.1 United States
10.1.1 Forecast
10.1.2 Key Events
10.1.3 Drivers And Barriers
11 Appendix
11.1 Bibliography
PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022

5. 11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Do Patients
11.4.2 Percent Drug-treated Patients
11.4.3 Drugs Included In Each Therapeutic Class
11.4.4 Launch And Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Pricing Of Pipeline Agents
11.5 Physicians And Specialists Included In This Study
11.6 About The Authors
11.6.1 Author
11.6.2 Reviewer
11.6.3 Epidemiologist
11.6.4 Global Head Of Healthcare
11.7 About Globaldata
11.8 Contact Us
11.9 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022